Related Experiment Video
Updated: May 6, 2026
Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Surface-Engineered Porous Silicon Nanoparticles for Targeted Osteosarcoma Therapy
Mona A Abdelmoneem1,2,3, Lars Esser4,5, Marcin Wojnilowicz4,5
1Department of Materials Science & Engineering, Monash University, Clayton, Victoria 3168, Australia.
Abstract:
Osteosarcoma, an aggressive primary bone cancer, poses significant clinical challenges due to limited treatment options. Targeted nanocarriers have emerged as a promising strategy to facilitate the precise delivery of chemotherapeutics to deeply seated tissues like bone. In this study, we developed a bone-targeted nanocarrier for doxorubicin delivery using alendronate-conjugated poly(N-(2-hydroxypropyl)acrylamide) (ALN-PolyHPAm)-functionalized porous silicon nanoparticles. These tailored nanoparticles, featuring hydrophobic pores, showed a high drug-loading capacity and sustained, pH-responsive doxorubicin release. The alendronate-decorated PolyHPAm@D-pSiNPs displayed excellent antifouling properties while maintaining a strong hydroxyapatite-binding affinity in a hydroxyapatite-coated quartz crystal microbalance sensor; they also exhibited high cell association in human osteosarcoma cells (Saos-2) and selective binding to hydroxyapatite in a mineralized cell assay. Furthermore, doxorubicin-loaded ALN-PolyHPAm@D-pSiNPs displayed significantly higher in vitro cytotoxicity in Saos-2 cells compared to doxorubicin-loaded nontargeted PolyHPAm@D-pSiNPs and free doxorubicin. This developed bone-targeted pSiNP platform holds significant promise for the targeted osteosarcoma treatment.
Insights
Researchers developed novel bone-targeted nanoparticles for delivering doxorubicin chemotherapy to treat osteosarcoma. These alendronate-conjugated porous silicon nanoparticles show enhanced drug delivery and efficacy against cancer cells.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Oncology
Background:
- Osteosarcoma is an aggressive bone cancer with limited treatment options.
- Targeted nanocarriers offer a promising approach for delivering chemotherapy to bone.
- Developing effective drug delivery systems is crucial for improving osteosarcoma treatment outcomes.
Purpose of the Study:
- To develop and evaluate a bone-targeted nanocarrier system for doxorubicin delivery in osteosarcoma.
- To functionalize porous silicon nanoparticles with alendronate for enhanced bone targeting.
- To assess the drug loading, release kinetics, and in vitro efficacy of the targeted nanocarriers.
Main Methods:
- Synthesis of alendronate-conjugated poly(N-(2-hydroxypropyl)acrylamide)-functionalized porous silicon nanoparticles (ALN-PolyHPAm@D-pSiNPs).
- Evaluation of doxorubicin loading capacity, pH-responsive release, and antifouling properties.
- Assessment of hydroxyapatite-binding affinity and cellular uptake in Saos-2 osteosarcoma cells.
- In vitro cytotoxicity assays comparing targeted nanoparticles with non-targeted nanoparticles and free doxorubicin.
Main Results:
- The developed nanoparticles exhibited high doxorubicin loading capacity and sustained, pH-responsive drug release.
- ALN-PolyHPAm@D-pSiNPs demonstrated strong hydroxyapatite-binding affinity and selective uptake in osteosarcoma cells.
- Doxorubicin-loaded targeted nanoparticles showed significantly enhanced in vitro cytotoxicity against Saos-2 cells compared to controls.
Conclusions:
- The bone-targeted porous silicon nanoparticle platform effectively delivers doxorubicin for osteosarcoma treatment.
- Alendronate conjugation enhances nanoparticle targeting to bone tissue.
- This nanocarrier system holds significant promise for improving osteosarcoma therapy.
